BCYC - Bicycle Therapeutics plc News

Sectors

BCYC

Bicycle Therapeutics plc

4.17

1 x 4.17

12 x 4.18

bid

ask

0.01

0.36%

10:36 AM

timesize

Ytd	-41.03%
1y	-50.12%

4.13

day range

4.19

3.92

52 week range

9.18

Open	4.17	Prev Close	4.16	Low	4.13	High	4.19	Mkt Cap	288.68M
Vol	16.15K	Avg Vol	446.47K	EPS	-3.15	P/E	-1.32	Forward P/E	-3.09
Beta	1.55	Short Ratio	14.44	Inst. Own	92.44%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	04-30	50-d Avg	4.30	200-d Avg	5.78	1yr Est	29.55

BCYC News

businesswire.com

Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

businesswire.com

Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

businesswire.com

Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual M

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

zacks.com

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the

defenseworld.net

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 sha

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Analys

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rat

zacks.com

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC)

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure

zacks.com

Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Co

Bicycle Therapeutics (BCYC) is technically in oversold territory now, so the heavy selling pressure

businesswire.com

Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

businesswire.com

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financia

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has earned an average rating

businesswire.com

Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology P

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

businesswire.com

Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerag

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received a consensus rec

businesswire.com

Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain t

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceuti

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutic

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

defenseworld.net

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Broker

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) has received an average reco

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutic

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

newsfilecorp.com

ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - November 18, 2025) - Levi & Korsinsky notifies investors that

benzinga.com

Stocks That Hit 52-Week Lows On Monday

Monday's session saw 84 companies set new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

benzinga.com

Stocks That Hit 52-Week Highs On Friday

During the morning session on Friday, 178 stocks hit new 52-week highs.